Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2+ Advanced NSCLC
NCT02535507Phase 2Unknown
- Sponsor
- Tongji University
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Tongji University. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02535507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535507.